Wolf Group Capital Advisors Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Wolf Group Capital Advisors cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,712 shares of the biopharmaceutical company’s stock after selling 5,086 shares during the quarter. Gilead Sciences makes up approximately 1.4% of Wolf Group Capital Advisors’ investment portfolio, making the stock its 17th largest position. Wolf Group Capital Advisors’ holdings in Gilead Sciences were worth $4,226,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of GILD. Norges Bank acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $1,789,254,000. FMR LLC lifted its holdings in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. GAMMA Investing LLC lifted its holdings in Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock valued at $285,761,000 after acquiring an additional 2,532,070 shares during the period. Northern Trust Corp lifted its holdings in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after acquiring an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $207,340,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GILD. Wells Fargo & Company boosted their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Cantor Fitzgerald began coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price for the company. Finally, Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Stock Down 2.6%

NASDAQ GILD opened at $108.00 on Wednesday. The business has a fifty day moving average price of $105.88 and a 200 day moving average price of $102.49. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The company has a market cap of $134.34 billion, a P/E ratio of 22.74, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the prior year, the company earned ($1.32) EPS. The firm’s revenue was down .3% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s payout ratio is currently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the completion of the sale, the chief financial officer now owns 168,174 shares of the company’s stock, valued at approximately $17,893,713.60. The trade was a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,500 shares of company stock worth $5,236,245 in the last three months. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.